je.st
news
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Mercks HPV Vaccine, Available to Developing Countries through UNICEF Tender
2013-05-09 13:20:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has been awarded a significant portion of the UNICEF human papillomavirus (HPV) vaccine tender, and will provide sustained supply of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to GAVI-eligible countries. This agreement follows the GAVI Alliances earlier announcement that HPV vaccines would be included in its portfolio for the first time. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
through
types
human
Category:Biotechnology and Pharmaceuticals